More from Building Lifelong Athletes
In this episode, I try to cut through the noise of the cholesterol debate and walk through 150 years of vascular science. From ancient mummies to modern genetics, we examine how lipidology reached its consensus, the response-to-retention hypothesis, why ApoB particle count matters more than LDL cholesterol mass, and what landmark clinical trials reveal about cardiovascular risk.
Was Ancel Keys a visionary pioneer of preventive cardiology or the villain who triggered our metabolic health crisis? In this episode, I pull back the curtain on the real science, the controversial 1953 graph, hidden trial data, and sugar industry influence. We explore where Keys was decades ahead of his time, where his model failed, and what his legacy teaches us about navigating scientific dogma in clinical practice today.
In this episode, I break down the underlying science of cholesterol, lipoproteins, and heart disease. We'll cut through the online noise and examine how cholesterol actually moves through your bloodstream, why particle count (ApoB) matters more than total cholesterol weight, how statins and other medications work at the cellular level, and how plaque forms in atherosclerosis. Everything you need to understand lipidology 101.
Welcome back to the trenches! In our final breakdown of the 2026 ACC/AHA lipid guidelines, we are unpacking the pharmacology toolbox. From statins and ezetimibe to PCSK9 inhibitors and the nuances of side effects like SAMS, I want to give you the practical, evidence-informed strategies we need for our patients. We are all just trying to navigate this together.
In this episode, I'm breaking down sections 4.2.3 through 4.2.10 of the dense ACC/AHA dyslipidemia guidelines so you don't have to. We'll cut through the noise on the new PREVENT equations, risk enhancers, imaging, and algorithms for primary and secondary prevention. Let's get you equipped to handle these complex lipid management decisions in the clinic.